Franklin Resources Inc. Has $111.06 Million Holdings in Bausch Health Companies Inc. (NYSE:BHC)

Franklin Resources Inc. reduced its holdings in Bausch Health Companies Inc. (NYSE:BHC – Get Rating) by 6.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,684,065 shares of the company’s stock after selling 1,159,664 shares during the quarter. Franklin Resources Inc. owned approximately 4.89% of Bausch Health Companies worth $111,056,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Optiver Holding B.V. boosted its holdings in shares of Bausch Health Companies by 707.6% in the 3rd quarter. Optiver Holding B.V. now owns 4,054 shares of the company’s stock worth $28,000 after acquiring an additional 3,552 shares in the last quarter. Pacifica Partners Inc. lifted its holdings in Bausch Health Companies by 2,232.6% during the 4th quarter. Pacifica Partners Inc. now owns 5,015 shares of the company’s stock worth $31,000 after buying an additional 4,800 shares in the last quarter. Quadrant Capital Group LLC lifted its holdings in Bausch Health Companies by 420.1% during the 3rd quarter. Quadrant Capital Group LLC now owns 5,851 shares of the company’s stock worth $40,000 after buying an additional 4,726 shares in the last quarter. FMR LLC lifted its holdings in Bausch Health Companies by 58.3% during the 2nd quarter. FMR LLC now owns 10,057 shares of the company’s stock worth $84,000 after buying an additional 3,703 shares in the last quarter. Finally, HighTower Advisors LLC lifted its holdings in Bausch Health Companies by 24.2% during the 1st quarter. HighTower Advisors LLC now owns 10,763 shares of the company’s stock worth $245,000 after buying an additional 2,100 shares in the last quarter. 66.99% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on BHC. Jefferies Financial Group upped their price objective on Bausch Health Companies from $7.00 to $9.50 in a report on Monday. StockNews.com began coverage on Bausch Health Companies in a report on Thursday, May 18th. They set a “hold” rating on the stock. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Bausch Health Companies currently has an average rating of “Hold” and a consensus price target of $8.88.

Bausch Health Companies Stock Performance

Shares of Bausch Health Companies stock opened at $8.20 on Friday. The firm has a fifty day moving average of $7.32 and a two-hundred day moving average of $7.55. Bausch Health Companies Inc. has a 52 week low of $4.00 and a 52 week high of $10.23. The company has a current ratio of 1.08, a quick ratio of 0.77 and a debt-to-equity ratio of 139.36.

Bausch Health Companies (NYSE:BHC – Get Rating) last issued its earnings results on Thursday, February 23rd. The company reported $1.02 EPS for the quarter, beating the consensus estimate of $0.92 by $0.10. The company had revenue of $2.19 billion during the quarter, compared to analysts’ expectations of $2.12 billion. Bausch Health Companies had a negative net margin of 4.38% and a positive return on equity of 381.67%. As a group, equities research analysts forecast that Bausch Health Companies Inc. will post 3.37 earnings per share for the current year.

Bausch Health Companies Profile

(Get Rating)

Bausch Health Cos., Inc engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb.